Cargando…

The use of S100 proteins testing in juvenile idiopathic arthritis and autoinflammatory diseases in a pediatric clinical setting: a retrospective analysis

BACKGROUND: Serum phagocyte-derived alarmins S100A8/9 and S100A12 are considered useful for the assessment of inflammatory diseases. Our study evaluated the use of S100 proteins in a pediatric clinical setting for estimating disease activity and supporting diagnosis. METHODS: Patients (n = 136) who...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aljaberi, Najla, Tronconi, Elena, Schulert, Grant, Grom, Alexei A., Lovell, Daniel J., Huggins, Jennifer L., Henrickson, Michael, Brunner, Hermine I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966841/ https://www.ncbi.nlm.nih.gov/pubmed/31948488 http://dx.doi.org/10.1186/s12969-020-0398-2

Ejemplares similares

Differential monocyte microrna expression profiles in children with active systemic juvenile idiopathic arthritis
por: Schulert, Grant, et al.
Publicado: (2014)

Proceedings from the 2(nd) Next Gen Therapies for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome symposium held on October 3-4, 2019
por: Canna, Scott W., et al.
Publicado: (2020)

Population-level single-cell genomics reveals conserved gene programs in systemic juvenile idiopathic arthritis
por: Verweyen, Emely L., et al.
Publicado: (2023)

Autoinflammatory genes and susceptibility to psoriatic juvenile idiopathic arthritis
por: Day, T G, et al.
Publicado: (2008)

Neutrophils From Children With Systemic Juvenile Idiopathic Arthritis Exhibit Persistent Proinflammatory Activation Despite Long-Standing Clinically Inactive Disease
por: Brown, Rachel A., et al.
Publicado: (2018)

Mouse models of systemic juvenile idiopathic arthritis and macrophage activation syndrome
por: Inoue, Natsumi, et al.
Publicado: (2023)

Autoinflammatory gene polymorphisms and susceptibility to UK juvenile idiopathic arthritis
por: Hinks, Anne, et al.
Publicado: (2013)

Imaging findings of juvenile idiopathic arthritis and autoinflammatory diseases in children
por: Tsujioka, Yuko, et al.
Publicado: (2023)

Tapering and withdrawal of tocilizumab in patients with systemic juvenile idiopathic arthritis in inactive disease: results from an alternative dosing regimen in the TENDER study
por: De Benedetti, F, et al.
Publicado: (2014)

The autoimmune burden in juvenile idiopathic arthritis
por: Tronconi, Elena, et al.
Publicado: (2017)

Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes
por: Urien, Saik, et al.
Publicado: (2013)

Complications of complications: diagnosis and treatment of recurrent macrophage activation syndrome in a patient with well-controlled systemic juvenile idiopathic arthritis
por: Macaraeg, Marci, et al.
Publicado: (2023)

Prevalence of co-existing autoimmune disease in juvenile idiopathic arthritis: a cross-sectional study
por: Simon, Teresa A., et al.
Publicado: (2020)

Prevalence of autoimmune diseases and other associated conditions in children and young adults with juvenile idiopathic arthritis
por: Lovell, Daniel J, et al.
Publicado: (2021)

Interferon-gamma (IFNy) in macrophage activation syndrome (MAS) associated with systemic juvenile idiopathic arthritis (sJIA). High levels in patients and a role in a murine mas model
por: Bracaglia, Claudia, et al.
Publicado: (2014)

Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy
por: Brachat, Arndt H., et al.
Publicado: (2017)

Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis
por: Ruperto, Nicolino, et al.
Publicado: (2021)

PReS-FINAL-2022: Juvenile idiopathic arthritis after allogeneic bone marrow transplantation: a case report
por: Tronconi, E, et al.
Publicado: (2013)

Reasons for Initiating Canakinumab among Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease in the U.S. Real-World Settings
por: Hur, Peter, et al.
Publicado: (2021)

Infectious adverse effects during treatment with IL-1 inhibitors in patients with systemic juvenile idiopathic arthritis and autoinflammatory diseases
por: Fernandez-Silveira, Laura, et al.
Publicado: (2014)

Natural Killer Cells in Systemic Autoinflammatory Diseases: A Focus on Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome
por: Vandenhaute, Jessica, et al.
Publicado: (2020)

Mutations in the MTHFR gene are not associated with Methotrexate intolerance in patients with juvenile idiopathic arthritis
por: Scheuern, Andrea, et al.
Publicado: (2016)

A case of systemic juvenile idiopathic arthritis with pulmonary hemosiderosis secondary to recurrent macrophage activation syndrome or a new autoinflammatory syndrome?
por: Barut, K, et al.
Publicado: (2015)

Juvenile idiopathic arthritis
por: Bhatt, Krupa H, et al.
Publicado: (2014)

Juvenile Idiopathic Arthritis
por: Barut, Kenan, et al.
Publicado: (2017)

Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis
por: Ravelli, Angelo, et al.
Publicado: (2016)

Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis
por: Ruperto, Nicolino, et al.
Publicado: (2021)

Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications
por: Ombrello, Michael J, et al.
Publicado: (2017)

Land-Jump Performance in Patients with Juvenile Idiopathic Arthritis (JIA): A Comparison to Matched Controls
por: Ford, Kevin R., et al.
Publicado: (2009)

Timing matters: real-world effectiveness of early combination of biologic and conventional synthetic disease-modifying antirheumatic drugs for treating newly diagnosed polyarticular course juvenile idiopathic arthritis
por: Huang, Bin, et al.
Publicado: (2020)

PReS-FINAL-2001: The impact of adalimumab on growth in patients with juvenile idiopathic arthritis
por: Ruperto, N, et al.
Publicado: (2013)

Neutrophils extracellular traps formation may serve as a biomarker for disease activity in oligoarticular juvenile idiopathic arthritis: a pilot study
por: Heshin-Bekenstein, Merav, et al.
Publicado: (2023)

The American English version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
por: Lovell, Daniel J., et al.
Publicado: (2018)

Immature cell populations and an erythropoiesis gene-expression signature in systemic juvenile idiopathic arthritis: implications for pathogenesis
por: Hinze, Claas H, et al.
Publicado: (2010)

Canakinumab treatment shows maintained efficacy in systemic juvenile idiopathic arthritis patients
por: Wulffraat, NM, et al.
Publicado: (2014)

Urine S100 proteins as potential biomarkers of lupus nephritis activity
por: Turnier, Jessica L., et al.
Publicado: (2017)

Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial
por: Brunner, Hermine I, et al.
Publicado: (2023)

Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate
por: Lovell, Daniel J, et al.
Publicado: (2020)

Complement analysis reveals new biomarkers in patients with juvenile idiopathic arthritis
por: Brunner, Juergen, et al.
Publicado: (2014)

Autoinflammatory Features in Gouty Arthritis
por: Galozzi, Paola, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v93tm1ic50s8rlqpo7kdcd0jd0